The most common adverse effects in a study investigating<unk>  monotherapy were diarrhoea (14% of patients, as compared to 9% under placebo), hyponatraemia (low blood sodium levels; 6% versus 2%), headache (9% versus 3%), and high blood pressure (16% versus 8%).
Ramucirumab
Ustekinumab
Emapalumab
Olaratumab
Evolocumab
Avelumab
Anifrolumab
Burosumab